Who are HM11260C's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BGB-16673, CKD-701, CKD-843 dose#1, Placebo + fulvestrant, Placebo,Fulvestrant,Goserelin acetate, faslodex dummy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hm11260c.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

HM11260C — Competitive Intelligence Brief

HM11260C (HM11260C) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective Estrogen Receptor Degrader (SERD). Area: Oncology.

phase 3 Selective Estrogen Receptor Degrader (SERD) Estrogen Receptor (ER) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HM11260C (HM11260C) — Hanmi Pharmaceutical Company Limited. HM11260C is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HM11260C TARGET	HM11260C	Hanmi Pharmaceutical Company Limited	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
BGB-16673	BGB-16673	BeOne Medicines	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
CKD-701	CKD-701	Chong Kun Dang Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
CKD-843 dose#1	CKD-843 dose#1	Chong Kun Dang Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
Placebo + fulvestrant	Placebo + fulvestrant	Nanjing Chia-tai Tianqing Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
Placebo,Fulvestrant,Goserelin acetate	Placebo,Fulvestrant,Goserelin acetate	Ahon Pharmaceutical Co., Ltd.	phase 3	Selective estrogen receptor degrader (SERD) + GnRH agonist combination	Estrogen receptor (ER) + GnRH receptor
faslodex dummy	faslodex dummy	AstraZeneca	phase 3	Selective estrogen receptor degrader (SERD)	Estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective Estrogen Receptor Degrader (SERD) class)

Chong Kun Dang Pharmaceutical · 7 drugs in this class
Hanmi Pharmaceutical Company Limited · 2 drugs in this class
Dong-A ST Co., Ltd. · 1 drug in this class
Genor Biopharma Co., Ltd. · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
AstraZeneca · 1 drug in this class
Nanjing Chia-tai Tianqing Pharmaceutical · 1 drug in this class
BeOne Medicines · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HM11260C — Competitive Intelligence Brief. https://druglandscape.com/ci/hm11260c. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab